Antimicrobial activity of ceftobiprole against Gram-negative and Gram-positive pathogens: Results from INVITA-A-CEFTO Brazilian study

Brazilian Journal of Infectious Diseases

Volumn 15, Issue 4, 2011, Pages 339-348

  Cereda, Rosângela Ferraz ^a   Azevedo, Heber Dias ^b   Girardello, Raquel ^d   Xavier, Danilo Elias ^d   Gales, Ana C ^d,e,f,g,h  

^a Medicine   (Brazil)

^b

^c Brazil

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^f HOSPITAL SAMARITANO   (Brazil)

^g Hospital Matter Dei   (Brazil)

^h São Domingos Hospital   (Brazil)

Author keywords

Brazil; Cephalosporins; Gram negative aerobic bacteria; Methicillin resistant Staphylococcus aureus

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; CIPROFLOXACIN; DORIPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BRAZIL; BROTH DILUTION; CONTROLLED STUDY; ENTEROBACTER; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BRAZIL; CEPHALOSPORINS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 80052397838     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1590/S1413-86702011000400007     Document Type: Article

References (20)

1. Endimiani A., Perez F., Bonomo R.A. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther 2008, 6(6):805-824.
2. Yahav D., Paul M., Fraser A., Sarid N., Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007, 7(5):338-348.
3. Gales A.C., Sader H.S., Ribeiro J., Zoccoli C., Barth A., Pignatari A.C. Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008). Braz J Infect Dis 2009, 13(2):90-98.
4. Noel G.J. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect 2007, 13(Suppl2):25-29.
5. Davies T.A., Page M.G., Shang W., Andrew T., Kania M., Bush K. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 2007, 51(7):2621-2624.
6. Fritsche T.R., Sader H.S., Jones R.N. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis 2008, 61(1):86-95.
7. Bogdanovich T., Ednie L.M., Shapiro S., Appelbaum P.C. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005, 49(10):4210-4219.
8. Bogdanovich T., Clark C., Ednie L., et al. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 2006, 50(6):2050-2057.
9. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36(5):309-332.
10. M7-A8 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2009, Clinical and Laboratory Standards Institute, PA: CLSI, Wayne. 18th edition.
11. Performance standards for antimicrobial susceptibility testing: 21st informational supplement 2011, Clinical and Laboratory Standards Institute, PA: CLSI, Wayne, (M100-S21).
12. Doribax[package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc, 2007.
13. Tygacil [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc, 2005.
14. Rossolini G.M., Dryden M.S., Kozlov R.S., et al. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. J Antimicrob Chemother 2011, 66(1):151-159.
15. Zhanel G.G., Voth D., Nichol K., Karlowsky J.A., Noreddin A.M., Hoban D.J. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother 2009, 64(2):364-369.
16. Jones R.N., Deshpande L.M., Mutnick A.H., Biedenbach D.J. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002, 50(6):915-932.
17. Queenan A.M., Shang W., Kania M., Page M.G., Bush K. Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob Agents Chemother 2007, 51(9):3089-3095.
18. Gales A.C., Menezes L.C., Silbert S., Sader H.S. Dissemination in distinct Brazilian regions of an epidemic carbapenemresistant producing SPM metallo-beta-lactamase. J Antimicrob Chemother 2003, 52(4):699-702.
19. Schimith Bier K.E., Luiz S.O., Scheffer M.C., et al. Temporal evolution of carbapenem-resistant Acinetobacter baumannii in Curitiba, southern Brazil. Am J Infect Control 2010, 38(4):308-314.
20. Andrade S.S., Sader H.S., Barth A.L., et al. Antimicrobial susceptibility patterns of Gram-negative bacilli isolated in Brazilian hospitals participating in the SENTRY Program (2003-2008). Braz J Infect Dis 2008, 12(Suppl 2):3-9.